D07.5
Carcinoma in situ of prostate
Clinical Classification Guidelines
Inclusion Terms
- Prostatic intraepithelial neoplasia III (PIN III)
- Severe dysplasia of prostate
Excludes Type 1
- dysplasia (mild) (moderate) of prostate (N42.3-)
- prostatic intraepithelial neoplasia II [PIN II] (N42.3-)
Medical Intelligence & Overview
Carcinoma in situ of the prostate, classified under ICD-10 code D07.5, is a condition characterized by abnormal cell growth within the prostate gland that has not yet spread beyond the prostate tissue. It is also known as prostatic intraepithelial neoplasia III (PIN III) and involves severe dysplasia, which indicates significant abnormality in the cells' appearance and organization. Although it is not invasive cancer, the presence of carcinoma in situ can be a precursor to invasive prostate cancer if left unmanaged. Understanding this condition is crucial for early detection and appropriate management.
Causes & Symptoms
Clinical Causes: Genetic mutations affecting prostate cell regulation Age-related cellular changes, especially in men over 50 Hormonal factors, particularly androgens influencing prostate cell growth Environmental exposures, including certain chemicals and toxins Lifestyle factors such as diet high in saturated fats and low in fruits and vegetables
Key Symptoms: Often no noticeable symptoms in the early stages Elevated prostate-specific antigen (PSA) levels found through blood tests Detection may occur during routine prostate screenings or biopsies Possible discomfort or difficulty during urination if associated with other prostate issues No specific symptoms directly attributable to carcinoma in situ
Diagnostic & Treatment
Diagnosis Path: Prostate-specific antigen (PSA) blood test to detect abnormal levels Digital rectal exam (DRE) to palpate abnormalities in prostate size or texture Prostate biopsy, where tissue samples are examined under a microscope for cellular abnormalities indicative of PIN III Histopathological analysis to confirm the severity of dysplasia and rule out invasive cancer Imaging tests like MRI may be used to assess prostate anatomy and identify areas of concern
Treatment Protocols: Active surveillance with regular PSA testing and prostate biopsies to monitor changes Potential use of medications such as 5-alpha-reductase inhibitors to slow cellular growth Lifestyle modifications, including dietary changes and exercise, to support prostate health Surgical intervention or radiation therapy generally reserved for cases where progression to invasive cancer is confirmed Consultation with urologists or oncologists for personalized treatment planning
Clinical Advice & FAQs
Billing Guidance
Is D07.5 a billable ICD-10 code?
Yes, D07.5 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report D07.5?
Clinical documentation must specify the nature of Carcinoma in situ of prostate and any associated comorbidities for accurate reporting.
Cite this Clinical Reference